alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 126–150 of 452 studies in Neurobiology of Aging (page 6 of 19) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of these 452 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

APOE differentially moderates cerebrospinal fluid and plasma phosphorylated tau181 associations with multi-domain cognition

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurobiology of aging 2023-01-18

Biofluid markers of phosphorylated tau181 (p-tau181) are increasingly popular for the detection of early Alzheimer's pathologic changes. 3 key findings →

Participants: 727 Evidence: low

Full summary, score breakdown and related studies → Original source

Genetic screening in early-onset Alzheimer's disease identified three novel presenilin mutations

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurobiology of aging 2019-01-29

Mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP) are major genetic causes of early-onset Alzheimer's disease (EOAD). 1 key finding →

Participants: 68 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Mutation screening in Chinese patients with familial Alzheimer's disease by whole-exome sequencing

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurobiology of aging 2018-12-06

Familial Alzheimer's disease (FAD) is characterized by a positive family history of dementia and typically occurs at an early age with an autosomal dominant pattern of inheritance. 2 key findings →

Participants: 15 Evidence: low

Full summary, score breakdown and related studies → Original source

Metacognition, cortical thickness, and tauopathy in aging

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurobiology of aging 2022-06-25

We investigated self-rating of cognitive task performance (self-appraisal) and the difference between self-rating and actual task performance (appraisal discrepancy) in cognitively healthy older adults and their relationship with cortical thickness and Alzheimer's disease (AD) biomarkers, amyloid and tau. 4 key findings →

Participants: 151 Evidence: low

Full summary, score breakdown and related studies → Original source

Multimodal in vivo and postmortem assessments of tau in Lewy body disorders

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurobiology of aging 2020-08-21

We compared regional retention of 18F-flortaucipir between 20 patients with Lewy body disorders (LBD), 12 Alzheimer's disease patients with positive amyloid positron emission tomography (PET) scans (AD+Aβ) and 15 healthy controls with negative amyloid PET scans (HC-Aβ). 1 key finding →

Participants: 20 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Astrogliosis and episodic memory in late life: higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurobiology of aging 2021-02-26

Astrocytes play a formative role in memory consolidation during physiological conditions; when dysregulated, astrocytes release glial fibrillary acidic protein (GFAP), which has been linked with negative memory outcomes in animal studies. 3 key findings →

Participants: 69 Evidence: low

Full summary, score breakdown and related studies → Original source

Altered structural network organization in cognitively normal individuals with amyloid pathology

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurobiology of aging 2017-12-07

Recent findings show that structural network topology is disrupted in Alzheimer's disease (AD), with changes occurring already at the prodromal disease stages. 2 key findings →

Participants: 299 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurobiology of aging 2013-08-15

In this study we compared Pittsburgh compound-B (PIB) positron emission tomography (PET) amyloid imaging, fluorodeoxyglucose PET for metabolism, and magnetic resonance imaging (MRI) for structure to predict conversion from amnestic mild cognitive impairment (MCI) to Alzheimer's dementia using data from the Alzheimer's Disease Neuroimaging Initiative cohort. 5 key findings →

Participants: 29 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Neurobiology of aging 2005-03-24

Identifying pre-clinical Alzheimer's disease (AD) in subjects with mild cognitive impairment (MCI) is a major issue in clinical diagnosis. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A rare coding variant in TREM2 increases risk for Alzheimer's disease in Han Chinese

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Neurobiology of aging 2016-03-03

Two recent studies have identified that a rare coding variant (p.R47H) in exon 2 of triggering receptor expressed on myeloid cells 2 (TREM2) gene is associated with Alzheimer's disease (AD) susceptibility in Caucasians. 4 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Serum neurotrophins--a study on the time course and influencing factors in a large old age sample

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Neurobiology of aging 2006-08-01

The neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) are important mediators of brain and neuronal development, the maintenance of homeostatic conditions in the adult nervous system, and the complex interplay of central and peripheral physiological and pathophysiological factors. 4 key findings →

Participants: 465 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Neurobiology of aging 2006-05-11

This review reports correlations between four independent fields related to inflammation and Alzheimer disease: fundamental pathology, epidemiology, transgenic animal studies and clinical trials. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Associations among cognitive performance, VCAM-1, and GFAP in black adults: The ARCHES study

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Neurobiology of Aging 2026-07-07

Astrocytic injury and endothelial activation are interconnected processes within the neurovascular system that may contribute to variability in cognitive performance among cognitively unimpaired adults. 3 key findings →

Design: cross-sectional Participants: 313 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Neurobiology of Aging 1997-07-01

This report summarizes the consensus recommendations of a panel of neuropathologists from the United States and Europe to improve the postmortem diagnostic criteria for Alzheimer’s disease. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Regional age-related atrophy after screening for preclinical alzheimer disease

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neurobiology of aging 2021-09-15

Brain atrophy occurs in aging even in the absence of dementia, but it is unclear to what extent this is due to undetected preclinical Alzheimer disease. 2 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Opposing roles of the triggering receptor expressed on myeloid cells 2 and triggering receptor expressed on myeloid cells-like transcript 2 in microglia activation

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neurobiology of aging 2016-03-16

Mutations in triggering receptor expressed on myeloid cells 2 (TREM2), which has been proposed to regulate the inflammatory responses and the clearance of apoptotic neurons and/or amyloid-β, are genetically linked to increased risk for late-onset Alzheimer's disease (AD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Silencing of TREM2 exacerbates tau pathology, neurodegenerative changes, and spatial learning deficits in P301S tau transgenic mice

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neurobiology of aging 2015-08-24

Tau pathology is a pathological hallmark for several neurodegenerative diseases including Alzheimer's disease and frontotemporal dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

3D maps localize caudate nucleus atrophy in 400 Alzheimer's disease, mild cognitive impairment, and healthy elderly subjects

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neurobiology of aging 2010-06-11

MRI research examining structural brain atrophy in Alzheimer's disease (AD) generally focuses on medial temporal and cortical structures, but amyloid and tau deposits also accumulate in the caudate. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events